interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Bortezomib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Bortezomib, and who makes it?

Bortezomib appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 16 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 3.7 and 19 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Bortezomib5 dosage-form groups in the Orange Book
16generic makers listed
  1. Bortezomib appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 16 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 3.7 and 19 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Injectable, Intravenous, Subcutaneous

Four or more generic makers listed

Brand listed as marketed: Velcade. 15 generic makers with 15 generic products listed as marketed; the first generic approval is dated 2 May 2022.

2000200520102015202020252030015brand 2003Apotex Inc, first approval 2 May 2022Eugia Pharma Specialities Ltd, first approval 2 May 2022Fresenius Kabi Usa Llc, first approval 2 May 2022Pharmascience Inc, first approval 2 May 2022Qilu Pharmaceutical Hainan Co Ltd, first approval 2 May 2022Zydus Pharmaceuticals Usa Inc, first approval 2 May 2022Dr Reddys Laboratories Ltd, first approval 26 July 2022Hospira Inc, first approval 26 July 2022Jiangsu Hansoh Pharmaceutical Group Co Ltd, first approval 26 July 2022Meitheal Pharmaceuticals Inc, first approval 26 July 2022Msn Laboratories Private Ltd, first approval 26 July 2022Somerset Therapeutics Llc, first approval 11 October 2022Hetero Labs Ltd Unit Vi, first approval 3 May 2024Vilin Bio Med Ltd, first approval 2 June 2025Hainan Shuangcheng Pharmaceuticals Co Ltd, first approval 17 December 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Apotex Inc2 May 20221
Eugia Pharma Specialities Ltd2 May 20221
Fresenius Kabi Usa Llc2 May 20221
Pharmascience Inc2 May 20221
Qilu Pharmaceutical Hainan Co Ltd2 May 20221
Zydus Pharmaceuticals Usa Inc2 May 20221
Dr Reddys Laboratories Ltd26 July 20221
Hospira Inc26 July 20221
Jiangsu Hansoh Pharmaceutical Group Co Ltd26 July 20221
Meitheal Pharmaceuticals Inc26 July 20221
Msn Laboratories Private Ltd26 July 20221
Somerset Therapeutics Llc11 October 20221

3 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Powder, Intravenous, Subcutaneous

One to three generic makers listed

Brand listed as marketed: Bortezomib. 1 generic maker with 2 generic products listed as marketed; the first generic approval is dated 6 January 2026.

20202025203001brand 2022Gland Pharma Ltd, first approval 6 January 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Gland Pharma Ltd6 January 20262

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

20202025203001brand 2022data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Powder, Intravenous

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

201520202025203001brand 2017data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Bortezomib. No generic is listed as marketed.

20202025203001brand 2024data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.